According to recent market research, during the 2020-2026 forecast period, the vaccine market is expected to grow at a compound annual growth rate of 14.7%, which has been accelerated by the recent COVID-19 pandemic.
The main challenges of the vaccine process include antigen transfer (the antigen transfer of organisms will produce frequent new mutations, which develop very rapidly, and then need to monitor, identify and recombine modified vaccine antigens or strains, usually with seasonal periodicity) , Scalability, robustness, efficiency, cost, and effectiveness and stability.
It is worth noting that hydroxypropyl beta-cyclodextrin (HPBCD): the key role of functional excipients (especially cyclodextrin) is arousing the interest of vaccine developers, who are seeking to overcome formulation challenges and rapid production safety Effective vaccine. "Cyclodextrins are a class of oligosaccharides produced from starch through enzymatic conversion," she said. "In particular, 2-hydroxypropyl-β-cyclodextrin (HPβCD) is entering therapeutic biological processes, final formulations and vaccine delivery, and is being used in some promising new fields. Work in these fields is still in progress. Very early stage." The currently marketed vaccines use methyl beta cyclodextrin and hydroxypropyl-β cyclodextrin. It is believed that cyclodextrin will play more roles in future technological development.